Drug development shouldn’t be guesswork, not when patients are waiting.
Pathos is building a next-generation biotech with AI at the core. Not as a feature, but as the operating system for how medicines get developed. We believe most drugs don't fail because the science was wrong. They fail because they were tested in the wrong patients, with the wrong assumptions, in trials that couldn't answer the real question: who benefits, and why?
Pathos exists to change that. We're building the largest foundation model in oncology and pairing it with proprietary AI systems, deep oncology expertise, and 200+ petabytes of multimodal data linked to patient outcomes, so we can make development decisions with more precision, much earlier.
This is not theoretical. We’re well-capitalized and have the leadership to build a generational company. We invest in and advance our own clinical-stage programs, using our AI platform to sharpen trial design, patient selection and biomarker strategy. So therapies reach the patients most likely to benefit, sooner.
How We Build
Pathos does not operate like a traditional biotech. There is no middle management. There are no layers of approval. The company is designed, from the ground up, around small teams of 2–4 subject matter experts who each command hundreds of AI agents to do the work that used to require dozens of people.
Everyone builds. Everyone ships. Every function at Pathos — from clinical execution to asset selection to the foundation model itself — runs on this model. Our product velocity delivers meaningful outcomes in hours instead of weeks. This is not a future aspiration. It is how we operate today.
The people who thrive here are operators: deep experts who can specify what needs to happen, orchestrate AI agents to execute at scale, and make high-judgment calls that compound over time. If you have spent your career building and shipping AI systems at scale, this is the environment where that experience becomes a superpower.
About the Role
The Medical Director is a member of the Clinical Development team, accountable for the design, execution, oversight, and analysis of Pathos clinical trials. You will translate the predictions of the Oncology Foundation Model into protocols that ask the right scientific questions of the right patients, and you will own medical monitoring, site interactions, and clinical strategy across the portfolio.
You will work closely with R&D, Translational Medicine, Biomarker, and other internal teams to embed the right biomarker studies into every protocol and to correlate clinical and translational findings into the next development decision. You will partner daily with each asset team to shape clinical strategy and provide medical and scientific judgment to the rest of the company as a working leader. You will report to the Chief Development Lead.
This role sits at the intersection of deep oncology medicine and an AI native operating model. You will spend less time chasing processes and more time on the medical questions that move programs forward, because Foundry and a fleet of AI agents absorb the document drafting, data triage, literature surveillance, and coordination work that traditionally consumed a Medical Director's calendar.
What You Will Do
Own medical monitoring and patient safety
Drive clinical strategy and protocol design
Execute trials with discipline
Author regulatory and scientific content
Build external scientific presence
Who You Are
Minimum Qualifications
Nice to Have
Location
The preferred location for this position is in our New York City HQ, though exceptional remote candidates will also be considered.
El rango de pago para este puesto es:
250,000 - 320,000 USD por year (New York Office)
Clinical
New York City, NY
Compartir en: